Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

Figure 1

Co-primary endpoints. Kaplan-Meier distant recurrence-free survival (DRFS) survival curves for breast-conserving surgery cases. Solid lines, Mammostrat® score low risk; dotted lines, Mammostrat® score medium risk; grey lines, Mammostrat® score high risk. (a) Estrogen receptor (ER)-positive, node-negative breast cancers treated with adjuvant tamoxifen only. (b) ER-positive, tamoxifen-treated breast cancers (any nodal status).

Back to article page